trending Market Intelligence /marketintelligence/en/news-insights/trending/Lzmz0ZnVhlPcAwqx7ztKqw2 content esgSubNav
In This List

Retrophin names CEO

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Retrophin names CEO

Retrophin Inc. appointed Eric Dube president and CEO, effective Jan. 4.

Prior to joining Retrophin, Dube was president of North America at ViiV Healthcare, a GlaxoSmithKline PLC unit.

Dube succeeds Stephen Aselage, who is retiring. Aselage, who has been CEO since 2014, will continue to serve on Retrophin's board.

Dube will also serve on the board of the San Diego-based biopharmaceutical company, which develops therapies for rare diseases.